{
  "ticker": "JNJ",
  "target_date": "2025-11-06",
  "actual_date": "2025-11-06",
  "collected_at": "2025-12-08T12:30:00.231223",
  "price": {
    "open": 185.58,
    "high": 186.34,
    "low": 184.2,
    "close": 185.79037475585938,
    "volume": 6767400,
    "change_1d_pct": 0.52,
    "change_7d_pct": 0.02,
    "change_30d_pct": 5.2
  },
  "technicals": {
    "rsi_14": 32.05,
    "sma_20": 188.71,
    "sma_50": 182.91,
    "macd": 0.493,
    "macd_signal": 1.455,
    "macd_histogram": -0.963,
    "bb_upper": 193.76,
    "bb_lower": 183.66,
    "price_vs_sma20_pct": -1.55,
    "price_vs_sma50_pct": 1.58,
    "volume_ratio": 0.82
  },
  "fundamentals": {
    "market_cap": 487978598400,
    "pe_ratio": 19.550194,
    "forward_pe": 19.107546,
    "price_to_book": 6.147449,
    "price_to_sales": 5.295539,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.54,
    "pct_from_52w_low": 43.97
  },
  "macro": {
    "spy": {
      "price": 670.31,
      "change_1d_pct": -1.07,
      "change_7d_pct": -2.48
    },
    "vix": {
      "level": 19.5,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.09
    },
    "dollar_index": {
      "level": 99.73
    },
    "gold": {
      "price": 3979.9
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "DARZALEX FASPRO\u00ae is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma",
      "source": "Yahoo",
      "datetime": 1762466760,
      "summary": "Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).1 DARZALEX FASPRO\u00ae is the first and only approved",
      "url": "https://finnhub.io/api/news?id=49e7fe9f0b211ed839d2a8f38e0b2a7ce0a0103fa6c90b66d8acda7ebe2927ef"
    },
    {
      "headline": "How Recent Developments Are Shaping the Johnson & Johnson Investment Story",
      "source": "Yahoo",
      "datetime": 1762463913,
      "summary": "Johnson & Johnson's stock price target has seen a slight increase, with the Fair Value Estimate rising from $198.03 to $199.56 following recent analyst updates. This adjustment reflects the company's strong operational performance, a positive outlook on business portfolio changes, and encouraging si",
      "url": "https://finnhub.io/api/news?id=4668584a5d7aa27fd2b1206276d8ee1d408da79327909fff94dfd4c08d2a2022"
    },
    {
      "headline": "J&J\u2019s Caplyta wins MDD approval to extend revenue horizon",
      "source": "Yahoo",
      "datetime": 1762450498,
      "summary": "Caplyta\u2019s MDD label extension marks the first approval since J&J acquired the drug in a $14.6bn buyout.",
      "url": "https://finnhub.io/api/news?id=f9045d21e8f81c2c5ff2901fd011ef3e93e1fa7468ffd3134385c7b9679c2413"
    },
    {
      "headline": "Texas Attorney General Files Motion to Stop Kenvue From Paying November Dividends",
      "source": "Yahoo",
      "datetime": 1762450299,
      "summary": "Attorney General Ken Paxton filed a motion in a Texas District court on Wednesday to prevent Kenvue",
      "url": "https://finnhub.io/api/news?id=a7b65aa8b85454b1cba97080f96eaefc4e587f246697880837c8b65972dec71c"
    },
    {
      "headline": "AstraZeneca to pour $50bn into US ahead of New York listing as UK investment plans stall",
      "source": "Yahoo",
      "datetime": 1762447176,
      "summary": "The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.",
      "url": "https://finnhub.io/api/news?id=5a4f4ef4c7913f9ed0ce6a8873e8c10c2c347cca6d1e8fb0ffe4bcfbc4c07e45"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "10-Q",
      "date": "2025-10-22",
      "description": "jnj-20250928.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000209/jnj-20250928.htm"
    },
    {
      "form": "4",
      "date": "2025-10-20",
      "description": "xslF345X05/wk-form4_1761002033.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000204/xslF345X05/wk-form4_1761002033.xml"
    },
    {
      "form": "8-K",
      "date": "2025-10-14",
      "description": "jnj-20251014.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/jnj-20251014.htm"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627547.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000196/xslF345X05/wk-form4_1757627547.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627315.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000194/xslF345X05/wk-form4_1757627315.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}